Search results for "Multiple sclerosis functional composite"

showing 2 items of 2 documents

Impact of dietary intervention on serum neurofilament light chain in multiple sclerosis

2021

Background and ObjectivesAdapted ketogenic diet (AKD) and caloric restriction (CR) have been suggested as alternative therapeutic strategies for multiple sclerosis (MS), but information on their impact on neuroaxonal damage is lacking. Thus, we explored the impact of diets on serum neurofilament light chain (sNfL) levels in patients with relapsing-remitting MS.MethodsWe retrospectively evaluated a prospective randomized controlled trial of 60 patients with MS who were on a common diet or ketogenic diet or fasting. We examined sNfL levels of 40 participants at baseline and at the end of the study after 6 months using single molecule array assay.ResultssNfL levels were investigated in 9 contr…

OncologyAdultMalemedicine.medical_specialty2041medicine.medical_treatmentNeurofilament lightArticlelaw.inventionMultiple Sclerosis Relapsing-RemittingRandomized controlled triallawNeurofilament ProteinsInternal medicineOutcome Assessment Health CareMedicineHumansProspective StudiesTrial registrationSingle cycleCaloric RestrictionRetrospective Studiesbusiness.industryMultiple sclerosisFastingMiddle Agedmedicine.disease322Clinical trialNeurologyMultiple sclerosis functional compositeFemaleNeurology (clinical)businessDiet KetogenicFunction and Dysfunction of the Nervous SystemKetogenic diet
researchProduct

Preservation of neuronal function as measured by clinical and MRI endpoints in relapsing-remitting multiple sclerosis: how effective are current trea…

2018

Approved medications for relapsing-remitting multiple sclerosis have shown to be effective in terms of their anti-inflammatory potential. However, it is also crucial to evaluate what long-term effects a patient can expect from current MS drugs in terms of preventing neurodegeneration. Here we aim to provide an overview of the current treatment strategies in MS with a specific focus on potential neuroprotective effects. Areas covered: Randomized, double-blind and placebo or referral-drug controlled phase 2a/b and phase 3 trials were examined; non-blinded phase 4 studies (extension studies) were included to provide long-term data, if not otherwise available. Endpoints considered were expanded…

Oncologymedicine.medical_specialtyAnti-Inflammatory AgentsNeuroimagingDiseaseNeuropsychological TestsPlaceboNeuroprotectionDisability Evaluation03 medical and health scienceschemistry.chemical_compoundMultiple Sclerosis Relapsing-Remitting0302 clinical medicineInternal medicineTeriflunomidemedicineHumansPharmacology (medical)030212 general & internal medicineNeuronsExpanded Disability Status Scalebusiness.industryGeneral NeuroscienceMultiple sclerosismedicine.diseaseMagnetic Resonance ImagingFingolimodNeuroprotective AgentsTreatment OutcomeMultiple sclerosis functional compositechemistryDisease ProgressionNeurology (clinical)businessImmunosuppressive Agents030217 neurology & neurosurgerymedicine.drugExpert Review of Neurotherapeutics
researchProduct